10-Q/A: Organon Amends Q1 Report, Citing Sales Practice Misconduct

Organon & Co. filed an amended quarterly report disclosing an internal investigation into improper Nexplanon sales practices, leading to management changes and identified material weaknesses in internal controls.

Summary

• Organon & Co. filed an amended Quarterly Report on Form 10-Q/A for Q1 2025, following an internal investigation by its Audit Committee into sales practices for Nexplanon.
• The investigation found that the company asked two U.S. wholesalers to purchase greater quantities of Nexplanon than demand in Q4 2022, Q3/Q4 2024, and Q1/Q2/Q3 2025, and waived inventory management fees.
• These practices resulted in an estimated net impact of $2 million on Nexplanon sales for Q1 2025, with $17 million from the practices offset by $15 million pulled forward from 2024.
• Without these sales practices, consolidated revenue for fiscal year 2024 and certain other relevant periods would have fallen short of company guidance and external expectations.
• The former CEO and leader of the U.S. commercial organization applied inappropriate pressure, withheld information, and violated the company's Code of Conduct, leading to their resignations and termination, respectively.
• Material weaknesses in internal control over financial reporting were identified as of December 31, 2024, and disclosure controls and procedures were deemed ineffective as of March 31, 2025.
• Despite the control weaknesses, the company stated there would be no restatement or revision to previously issued financial statements.
• Worldwide sales for the three months ended March 31, 2025, decreased by 7% to $1.513 billion, or 4% excluding unfavorable foreign exchange rates.
• Gross profit decreased by 12% to $841 million for the three months ended March 31, 2025, compared to $957 million in the prior year.
• The company acquired U.S. regulatory and commercial rights for Tofidence, a biosimilar to Actemra, from Biogen in March 2025 for an upfront payment of $51 million.
• The quarterly dividend was significantly reduced from $0.28 to $0.02 per share, with funds to be redirected to debt repayment and/or repurchase.

Sentiment

Score: 3

Explanation: The filing reveals significant corporate governance failures, including improper sales practices that artificially boosted revenue and material weaknesses in internal controls, leading to management changes. While some products show growth, overall sales and gross profit declined, and the dividend was drastically cut. The remediation plan is a positive step, but the underlying issues are severe.

Positives

• Acquisition of U.S. regulatory and commercial rights for Tofidence (tocilizumab-bavi), a biosimilar to Actemra, from Biogen in March 2025, expanding the biosimilars portfolio.
• Sales of Hadlima, a biosimilar to Humira, increased by 55% (57% ex-FX) to $47 million for Q1 2025, reflecting continued ramp-up since its July 2023 U.S. launch.
• Sales of Emgality/Rayvow increased by 229% (247% ex-FX) to $32 million for Q1 2025, benefiting from a full quarter of sales following the acquisition of distribution and promotion rights from Lilly in January 2024.
• Sales of Follistim AQ, a fertility treatment, increased by 49% (52% ex-FX) to $69 million for Q1 2025, driven by a one-time buy-in, demand increase, and favorable discount rates in the United States.
• Sales of Jada, a device for postpartum uterine bleeding, increased by 20% to $15 million for Q1 2025, due to continued uptake in the United States and favorable pricing.
• Net cash provided by operating activities remained strong at $75 million for Q1 2025.
• Restructuring initiatives are expected to result in approximately $200 million of annual savings.

Negatives

• Worldwide sales decreased by 7% to $1.513 billion for Q1 2025 compared to $1.622 billion in Q1 2024, a 4% decrease excluding foreign exchange impacts.
• Gross profit decreased by 12% to $841 million for Q1 2025, compared to $957 million in Q1 2024, due to unfavorable price, decreased sales volume, and foreign exchange translation.
• The company engaged in improper sales practices for Nexplanon, asking two U.S. wholesalers to purchase inventory in excess of demand, and waived inventory management fees.
• Without these improper sales practices, consolidated revenue for fiscal year 2024 and certain other relevant periods would have fallen short of company guidance and external expectations.
• Material weaknesses were identified in internal control over financial reporting as of December 31, 2024, and disclosure controls and procedures were deemed ineffective as of March 31, 2025.
• The former CEO and leader of the U.S. commercial organization applied inappropriate pressure, withheld relevant information, and violated the company's Code of Conduct.
• Sales of Atozet declined by 42% to $77 million for Q1 2025, primarily due to loss of exclusivity (LOE) in France and Spain, with continued significant decline anticipated in 2025.
• Sales of NuvaRing declined by 43% to $22 million for Q1 2025, due to ongoing generic competition and increased government discount rates in the United States, with continued decline expected.
• Sales of Ontruzant declined by 54% to $18 million for Q1 2025, due to normalized contracted volume in Brazil and lower demand in the United States.
• Sales of Singulair decreased by 24% to $74 million for Q1 2025, due to lower respiratory infections in China, lower demand in Japan, and mandatory annual price reductions in Japan.
• The quarterly dividend was significantly reduced from $0.28 to $0.02 per share, indicating a shift in capital allocation away from shareholder returns towards debt management.
• LOE negatively impacted sales by approximately $63 million during Q1 2025, primarily from Atozet and Rosuzet.

Risks

• Expanded brand and class competition in operating markets.
• Trade protection measures, import/export licensing, tariffs, trade sanctions, or similar restrictions by governments.
• Changes in U.S. and foreign federal, state, and local governmental funding allocations.
• Economic factors including inflation, interest rates, recessionary pressures, and foreign currency exchange rates.
• Market volatility, downgrades to U.S. government credit rating, changing political/geopolitical conditions, market contraction, boycotts, and sanctions.
• Difficulties with performance of third parties relied on for business growth.
• Failure of any supplier to provide substances, materials, or services as agreed, or increased cost of supply, manufacturing, packaging, and operations.
• Difficulties developing and sustaining relationships with commercial counterparties.
• Competition from generic products as products lose patent protection.
• Failure to retain market exclusivity for Nexplanon or obtain additional exclusivity in the United States after rod patents expire in 2027.
• Continued impact of the September 2024 loss of exclusivity (LOE) for Atozet.
• Restructurings or other disruptions at regulatory agencies like the FDA and SEC.
• Difficulties and uncertainties in implementing acquisition strategy or failure to recognize benefits of acquisitions.
• Pricing pressures globally, including managed care groups, judicial decisions, and governmental regulations related to Medicare, Medicaid, healthcare reform, pharmaceutical reimbursement, and pricing.
• Impact of higher selling and promotional costs.
• Changes in government laws and regulations, including those governing research, development, approval, manufacturing, supply, distribution, marketing, intellectual property, and environmental regulations.
• Efficacy, safety, or other quality concerns with marketed products leading to recalls, withdrawals, or declining sales.
• Delays or failures in demonstrating adequate efficacy and safety of product candidates in pre-clinical and clinical trials.
• Future actions of third-parties, including significant changes in customer relationships or spending patterns of healthcare purchasers.
• Legal factors, including product liability claims, antitrust litigation, governmental investigations, tax disputes, environmental claims, and patent disputes.
• Lost market opportunity from delays and uncertainties in clinical trials and regulatory approval processes.
• Failure by the company or third-party collaborators/suppliers to fulfill regulatory or quality obligations.
• Cyberattacks, failures, accidents, or security breaches of IT systems.
• Increased focus on privacy issues and evolving legislative/regulatory landscape for privacy and data protection.
• Changes in tax laws, including those related to foreign earnings.
• Impact of any future pandemic, epidemic, or similar public health threat.
• Loss of key employees or inability to recruit new employees.
• Changes in accounting pronouncements adverse to the company.
• Volatility of commodity prices, fuel, and shipping rates.
• Costs associated with the ongoing initiative to optimize the manufacturing and supply network, including accelerated depreciation, exit premiums, technology transfer costs, capital investment, and inventory stock bridges.

Future Outlook

The company anticipates a continued significant decline in sales of Atozet in 2025 due to loss of exclusivity. It also expects a continued decline in NuvaRing sales due to generic competition. Volume-based procurement in China is expected to continue impacting the established brands product portfolio for the next several quarters. The company plans to redirect funds from the reduced dividend to debt repayment and/or repurchase. An ongoing initiative to optimize the manufacturing and supply network, including exiting supply agreements from Merck through 2031, is expected to drive efficiencies, though associated costs are anticipated.

Management Comments

• We believe that our financing arrangements, future cash from operations, and access to capital markets will provide adequate resources to fund our future cash flow needs.
• Management will continue to evaluate the potential impacts of the shifting geopolitical and macroeconomic landscape on our business, results of operations, liquidity, and capital resources.
• The process of designing and maintaining effective internal control over financial reporting is a continuous effort that requires management to anticipate and react to changes in our business, economic, and regulatory environments and to expend significant resources.

Industry Context

The pharmaceutical industry continues to face challenges from generic competition and loss of exclusivity (LOE) for key products, as evidenced by Organon's significant sales declines for Atozet and NuvaRing. The biosimilars market, however, presents growth opportunities, with Organon actively expanding its portfolio through acquisitions like Tofidence and seeing strong ramp-up in Hadlima sales. Global macroeconomic factors, including inflation, interest rates, and foreign exchange volatility, along with geopolitical developments and regulatory disruptions, are creating a complex operating environment for pharmaceutical companies. The company's focus on women's health and established brands positions it in segments with varying competitive dynamics and pricing pressures.

Comparison to Industry Standards

• The acquisition of Tofidence, a biosimilar to Actemra, aligns with a broader industry trend of pharmaceutical companies expanding into the biosimilar market to offset revenue losses from patent expirations of branded drugs. Actemra (tocilizumab) is a significant biologic, and biosimilar competition is a standard development.
• The significant sales declines for Atozet and NuvaRing due to Loss of Exclusivity (LOE) and generic competition are typical challenges faced by pharmaceutical companies as their branded products mature. This is a common pattern seen across the industry for drugs like Humira (adalimumab), Remicade (infliximab), and Enbrel (etanercept), where biosimilars like Hadlima, Renflexis, and Brenzys are now competing.
• The identified material weaknesses in internal control over financial reporting and the inappropriate sales practices, particularly involving pressure to meet sales targets, highlight a failure in corporate governance and ethical conduct that is a serious concern and deviates from expected industry standards for transparency and integrity.
• The reduction of the quarterly dividend from $0.28 to $0.02 per share, with funds redirected to debt repayment, suggests a more conservative capital allocation strategy, which can be a response to financial pressures or a strategic pivot, but is a notable change in shareholder return policy.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Negative impact due to the disclosure of improper sales practices, material weaknesses in internal controls, and the significant reduction in the quarterly dividend from $0.28 to $0.02 per share, which signals financial pressure and a shift in capital allocation. The stock price is highly likely to be negatively impacted.
• Employees: Impacted by management changes, including the resignation of the former CEO and termination of the Head of U.S. Commercial & Government Affairs. Restructuring initiatives are also leading to headcount reductions, though expected to result in annual savings.
• Customers (Wholesalers): Directly involved in the improper sales practices, being asked to purchase excess inventory and receiving waivers for inventory management fees. This could strain relationships and impact future purchasing patterns.
• Regulatory Authorities (SEC): The filing is an amendment to address inaccurate/incomplete prior disclosures, indicating increased scrutiny and potential for further regulatory action or investigation.
• Investment Professionals/Analysts: The findings necessitate a re-evaluation of the company's financial reporting reliability and corporate governance, impacting their assessment of the company's value and risk profile.

Next Steps

• Implement measures to improve internal control over financial reporting and remediate identified material weaknesses.
• Enhance the company's Code of Conduct, compliance training, and Annual Ethics and Policy Certifications.
• Implement additional representations within the Quarterly Financial Certification Questionnaire.
• Enhance Disclosure Committee responsibilities and provide incremental training.
• Implement additional and enhance existing sub-certifications and internal management representation letters.
• Enhance controls and implement written policies and procedures for management fee arrangements with wholesalers.
• Evaluate and enhance internal controls related to sales monitoring.
• Continue to evaluate the effectiveness of remedial measures and implement further improvements to internal control over financial reporting.
• Pay the reduced quarterly dividend of $0.02 per share on June 12, 2025.
• Redirect funds from the dividend payment to the repayment and/or repurchase of debt.
• Continue the ongoing initiative to optimize the manufacturing and supply network, including separating the supply chain from Merck through 2031.
• Assess and evaluate future commercial opportunities with Centergene.

Key Dates

Recommendation

The filing reveals severe corporate governance failures, including improper sales practices that artificially inflated revenue and led to material weaknesses in internal controls. The resignation of the CEO and termination of another senior executive underscore the seriousness of the misconduct. While the company is implementing a remediation plan, the immediate impact includes a significant 7% decline in worldwide sales, a 12% drop in gross profit, and a drastic 93% reduction in the quarterly dividend. These factors, combined with the explicit admission that prior reported revenues would have fallen short of guidance without the improper practices, indicate a fundamental issue with the reliability of past financial reporting and a challenging outlook. Investors should consider selling due to heightened risk, eroded trust, and deteriorating financial performance.

Keywords

Organon, OGN, SEC Filing, 10-Q/A, Quarterly Report, Amendment, Nexplanon, Sales Practices, Internal Investigation, Audit Committee, Material Weakness, Internal Control, Financial Reporting, Disclosure Controls, Management Changes, CEO Resignation, Biosimilars, Womens Health, Pharmaceuticals, Drug Wholesalers, Revenue, Gross Profit, Dividend Reduction, Tofidence, Actemra, Hadlima, Humira, Atozet, Loss of Exclusivity, Corporate Governance, Risk Management